凯普生物：10月13日召开董事会会议

Core Viewpoint - Capbio (SZ 300639) announced the convening of its sixth second board meeting on October 13, 2025, to discuss various proposals, including providing guarantees for its wholly-owned subsidiary and replacing some collateral under a syndicated loan [1] Financial Performance - For the first half of 2025, Capbio's revenue composition was as follows: molecular diagnostic products accounted for 67.65%, medical testing services for 29.07%, and medical service income for 3.27% [1] Market Position - As of the report, Capbio's market capitalization stood at 3.6 billion yuan [1]